Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stake Lessened by Values First Advisors Inc.

Values First Advisors Inc. lessened its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 51.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,032 shares of the company’s stock after selling 38,497 shares during the period. Values First Advisors Inc. owned about 0.05% of Zentalis Pharmaceuticals worth $109,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ZNTL. Verition Fund Management LLC boosted its position in Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after acquiring an additional 951,500 shares during the period. Primecap Management Co. CA lifted its position in shares of Zentalis Pharmaceuticals by 21.6% in the third quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after purchasing an additional 265,690 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Zentalis Pharmaceuticals by 138.5% during the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after purchasing an additional 353,384 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in Zentalis Pharmaceuticals by 126.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after purchasing an additional 127,868 shares in the last quarter. Finally, XTX Topco Ltd grew its position in Zentalis Pharmaceuticals by 8.7% during the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock valued at $714,000 after purchasing an additional 15,597 shares in the last quarter.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, Director Jan Skvarka acquired 60,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average price of $1.72 per share, with a total value of $103,200.00. Following the transaction, the director now owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ingmar Bruns bought 20,000 shares of the stock in a transaction on Thursday, February 6th. The stock was acquired at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the acquisition, the insider now directly owns 36,629 shares in the company, valued at approximately $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ZNTL has been the subject of a number of research analyst reports. UBS Group cut their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company reduced their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Guggenheim lowered their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Wedbush reaffirmed a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Finally, HC Wainwright reduced their price target on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $2.16 on Thursday. The stock’s 50 day simple moving average is $2.69 and its 200 day simple moving average is $3.14. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.61 and a twelve month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.36. Analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.